Development and Validation of Nomograms Predicting the Overall and the Cancer-Specific Survival in Endometrial Cancer Patients

Xingchen Li  
Peking University People's Hospital

Yangyang Dong  
1Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, China

Yuan Cheng  
1Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, China

Jingyi Zhou  
1Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, China.  
2Beijing Key Laboratory of Female Pelvic Floor Disorders Diseases, Beijing, 100044, China

Xiaotong Wu  
1Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, China.  
2Beijing Key Laboratory of Female Pelvic Floor Disorders Diseases, Beijing, 100044, China

Boqiang Shen  
1Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, China

Xiao Yang  
1Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, China

Zhiqi Wang  
1Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, China

Xiaoping Li  
1Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, China

Jianliu Wang ( wangjianliu@pkuph.edu.cn )  
1Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, China.  
2Beijing Key Laboratory of Female Pelvic Floor Disorders Diseases, Beijing, 100044, China

Research

Keywords: endometrial cancer, prognostic factor, cancer-specific survival, nomogram, SEER database

DOI: https://doi.org/10.21203/rs.3.rs-68463/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

**Background:** The present study was aimed at developing nomograms estimating the overall survival (OS) and cancer-specific survival (CSS) of endometrial cancer (EC)-affected patients.

**Patients and Methods:** We retrospectively collected 145,445 EC patients between 2004 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database. Independent prognostic factors were identified via univariate and multivariate Cox analyses. These risk factors were used to establish nomograms to predict 3- and 5-year OS and CSS rates. Internal and external data were used for validation. The predictive accuracy and discriminative ability were measured by using concordance index (C-index) and risk group stratification.

**Results:** A total of 63,510 patients were collected and randomly assigned into the training cohort (n=42,340) and validation cohort (n=21,170). Age at diagnosis, marital status, tumor size, histologic type, lymph node metastasis, tumor grade, and clinical stage were identified as independent prognostic factors for OS and CSS (p<0.05 according to multivariate Cox analysis) and were further used to construct the nomograms. The area under the receiver operating characteristics (ROC) curve was greater than that of International Federation of Gynecology and Obstetrics (FIGO) staging system for predicting OS (0.83 vs 0.73, p<0.01) and CSS (0.87 vs 0.79, p<0.01) in the training cohort. The stratification into different risk groups ensured a significant distinction between survival curves within different FIGO staging categories.

**Conclusion:** We constructed and validated nomograms that accurately predict OS and CSS in EC patients. The nomograms can be used for estimating OS and CSS of individual patients and establishing their risk stratification.

**Background**

Endometrial cancer (EC) is the most common gynecologic malignancy in the United States [1], with an increased number of cases also in China, especially in young women [2]. Several prognostic risk factors have been associated with the overall survival.

The most commonly used classification system in EC patients is the International Federation of Gynecology and Obstetrics (FIGO) staging system, in which patients with non-metastatic cancer are stratified based on the depth of myometrial invasion, cervical stromal invasion, as well as the extent of lymph node involvement [3]. However, survival of patients with the same clinical stage varies widely because this system considers the survival rate independently from other prognostic factors such as age, tumor grade, and histologic type [4, 5].

Nomogram is a statistical prediction tool that incorporates all prognostic factors to calculate the risk score of each patient and estimate the survival outcome for the individual, as has been widely demonstrated in other cancers such as breast cancer, gastric cancer, and ovarian cancer [6–8]. Therefore, considering the advancements in individualized cancer treatments, a more precise survival prediction
model for EC patients need further investigation. There are several established nomograms predicting lymph node metastasis\textsuperscript{9}, recurrence\textsuperscript{10}, and lymphatic dissemination\textsuperscript{11} in EC. Nomograms for predicting long-term survival outcome in EC are limited, and the most extensive used and validated nomogram is the Memorial Sloan-Kettering Cancer Center (MSKCC)\textsuperscript{12}. However, this nomogram was established in the past on a patient cohort. However, novel characteristics have been described from then. To our knowledge, a nomogram which includes available prognostic factors and that is based on a large cohort to predict the overall survival (OS) and cancer-specific survival (CSS) of EC patients has not recently been reported yet.

The Surveillance, Epidemiology, and End Results (SEER) database collects data from 18 cancer registries and covers about 30% of the US population\textsuperscript{13}. Using the SEER database, we established the OS and CSS nomograms on a nationwide, population-based cohort in EC patients from 2004 to 2015 in the current study. The nomograms incorporated independent prognostic factors for survival identified in EC, and precisely predicted 3- and 5-years overall and cancer-specific survival of individual EC patients. These nomograms contributed to a better risk stratification and clinical decision making.

\textbf{Materials And Methods}

\textbf{Patients cohort and variables}

Patients information was acquired by the National Cancer Institute SEER database, which was accessed via the SEER*Stat software (Version 8.3.5; NCI, Bethesda, MD). All data from the SEER were publicly available and exempt from approval by the institutional review board. We identified patients who underwent primary surgery for FIGO 2009 staging system that were diagnosed between 2004 and 2015. The inclusion criteria included the following: age at diagnosis > 18 years; endometrial cancer pathologically confirmed by histology (histological code: 8140–8389 for EEA, 8440–8499 for SEA). For patients who had a history of prior malignancy and or radiotherapy before surgery, were excluded. Clinical pathological features including patient age, year of diagnosis, marital status, tumor size, histological type, myometrial invasion, cervical stromal invasion, lymph node metastasis, tumor grade, clinical stage, chemotherapy, radiotherapy, time of survival, OS, and CSS were collected in the study. In addition, cases were excluded from the study if they had incomplete information on any of these characteristics. Age of the patients was stratified into 5 groups from 41 to 70 with a 10-year interval. The histological types were classified as endometrial endometrioid adenocarcinoma (EEA, ICD-O-3 codes: 8140–8389), serous endometrioid adenocarcinoma (SEA, ICD-O-3 codes: 8440–8499), and other types. Tumor size was categorized as \( \leq 2 \) cm, 2.1-5cm, 5.1-10cm, and > 10 cm. The eligible patients were randomly divided into a training cohort and a validation cohort according to the ratio of 2 to 1.

\textbf{Construction and validation of the nomogram}
Univariate and multivariate Cox regression analyses were used to identify the prognostic factors of the OS and the CSS in the training cohort. The independent risk factors were used to build the nomogram for the OS and CSS, respectively. The nomogram performance was assessed in both the training and validation groups by calculating discrimination and calibration criteria \(^{[14]}\). An index of concordance (C-index) between predicted probability and observed outcome was calculated to evaluate the predictive performance. C-index value ranged from 0.5 to 1.0, with 0.5 indicating a random likelihood and 1.0 indicating a perfect match. Generally, a C-index value of 0.7 or higher suggests an acceptable fit \(^{[15]}\). Patient differentiation was determined using the area under the receiver operating characteristic (ROC) curve. The area under the ROC curve (AUC) is a summary measure of the ROC that reflects the ability of a test to discriminate the outcomes across all possible levels of positivity. The AUC ranges from 0 to 1, and a model is considered to have a poor, fair, or good performance if the AUC lies between 0.5 to 0.6, 0.6 to 0.7 or is greater than 0.7, respectively. The AUC of clinical stage was compared with that of the nomogram in both the OS and the CSS group. A calibration plot was generated to visualize how far the predictions were from the actual outcomes, displaying mean nomogram-based predictions in the training and validation cohorts on the horizontal axis versus the actual observed survival probabilities.

**Risk group stratification based on the nomogram**

In addition to numerically comparing the discrimination ability of the nomogram, we evenly grouped the patients into 5 risk groups according to the risk score calculated by the nomograms (from the highest to the lowest) in the training set. These values were then applied to the validation set and the respective Kaplan-Meier survival curves were determined.

**Statistical analysis**

All the categorical variables were described as frequencies and percentages. Baseline of the clinical and the pathological characteristics of the patients were compared between the training and the validation cohort using a Chi-square or Fisher exact tests as appropriate. Univariate and multivariate Cox regression analyses were performed using the SPSS 22.0 (IBM Corp, USA). All variables that in univariate analysis showed a \(p\) value < 0.05 were selected for the multivariate analysis. Hazard ratios (HR) and corresponding 95% confidence interval (CI) of variables were also calculated. The independent factors were used to build the nomograms for 3- and 5-year OS and 3- and 5-year CSS. Calibration curves were constructed to compare consistency between predicted and observed survival. Construction of the nomogram, calibration, and survival curves were performed using the \texttt{rms}, \texttt{foreign}, and \texttt{survival} packages in R, version 3.5.1 (http://www.r-project.org).

**Results**

**Screening process and demographic characteristics of patients**
During the 2004–2015 time period, a total of 145,445 patients with endometrial cancer were identified from the SEER database. Of these, 63,510 patients were enrolled in this study according to the inclusion criteria and exclusion criteria listed in Fig. 1. These eligible patients were randomly divided into a training cohort (n = 42,340) and a validation cohort (n = 21,170). The demographic characteristics of the patients were listed in Table 1. In the training cohort, the mean age of the patients was 62.43 ± 11.66 years old. The mean tumor size was 6.56 ± 15.60 cm. For the marital status, a total of 22,726 (53.68%) patients were married, while 8,168 (19.29%) patients were single. Among these patients, 37,041 (87.48%) patients were diagnosed with EEA, 3,185 (7.52%) patients with SEA, and 2,114 (4.99%) patients were diagnosed with other cancer types. The myometrial invasion of most patients (27,721, 65.74%) was less than 50%. Most people were negative for cervical stromal invasion (33,797, 79.82%) and lymph node metastasis (37,500, 88.57%). As far as the clinical stage aspect, 70.46% people were at stage I, 8.17% were at stage II, 15.64% were at stage III, and 5.73 were at stage IV. The median survival time was 61.17 ± 40.99 months. The rest of the clinicopathologic characteristics of the patients in the training and validation group are listed in Table 1. There was no significant difference regarding all the enrolled variables between the two cohorts.
|                      | Training cohort | Validation cohort | \( P \) |
|----------------------|-----------------|-------------------|-------|
| Total number         | 42340           | 21170             |       |
| Mean + SD exp        |                 |                   |       |
| Age (years)          | 62.43 ± 11.66   | 62.37 ± 11.54     |       |
| Tumor size (cm)      | 6.56 ± 15.60    | 6.62 ± 15.76      |       |
| Survival months      | 61.17 ± 40.99   | 61.17 ± 40.98     |       |
|                      | N (%)           | N (%)             | 0.711 |
| Age (years)          |                 |                   |       |
| \( \leq 40 \)        | 1497 (3.54)     | 719 (3.40)        |       |
| 41–50                | 4241 (10.02)    | 2164 (10.22)      |       |
| 51–60                | 13001 (30.71)   | 6553 (30.95)      |       |
| 61–70                | 13533 (31.96)   | 6719 (31.74)      |       |
| > 70                 | 10068 (23.78)   | 5015 (23.69)      |       |
| Year of diagnosis    |                 |                   | 0.921 |
| 2004–2007            | 10840 (25.60)   | 5410 (24.28)      |       |
| 2008–2011            | 14395 (34.00)   | 7193 (33.98)      |       |
| 2012–2015            | 17105 (40.40)   | 8567 (41.47)      |       |
| Marital status       |                 |                   | 0.105 |
| Married              | 22726 (53.68)   | 11454 (54.10)     |       |
| Single               | 8168 (19.29)    | 4046 (19.11)      |       |
| Others               | 11446 (27.03)   | 5670 (26.78)      |       |
| Tumor size (cm)      |                 |                   | 0.243 |
| \( \leq 2 \)        | 10437 (24.65)   | 5171 (24.43)      |       |
| 2.1–5                | 20917 (49.40)   | 10463 (49.42)     |       |
| 5.1–10               | 8571 (20.24)    | 4321 (20.41)      |       |
| > 10                 | 2415 (5.70)     | 1215 (5.74)       |       |

EEA, endometrial endometrioid adenocarcinoma; SEA, serous endometrioid adenocarcinoma; LNM, lymph node metastasis
|                      | Training cohort | Validation cohort | \( P \) |
|----------------------|-----------------|-------------------|---------|
| **Histological type**|                 |                   | 0.418   |
| EEA                  | 37041 (87.48)   | 18468 (87.24)     |         |
| SEA                  | 3185 (7.52)     | 1621 (7.66)       |         |
| Other types          | 2114 (4.99)     | 1081 (5.11)       |         |
| **Myometrial invasion**|               |                   | 0.682   |
| < 50                 | 27721 (65.47)   | 13792 (65.14)     |         |
| ≥ 50                 | 14619 (34.53)   | 7378 (34.86)      |         |
| **Cervical stromal invasion**|       |                   | 0.959   |
| Negative             | 33797 (79.82)   | 16884 (79.75)     |         |
| Positive             | 8543 (20.18)    | 4286 (20.25)      |         |
| **LNM**              |                 |                   | 0.327   |
| Negative             | 37500 (88.57)   | 18775 (88.69)     |         |
| Positive             | 4840 (11.43)    | 2395 (11.31)      |         |
| **Grade**            |                 |                   | 0.545   |
| 1                    | 17748 (41.92)   | 8838 (41.75)      |         |
| 2                    | 12691 (29.97)   | 6262 (29.58)      |         |
| 3                    | 11901 (28.11)   | 6070 (28.67)      |         |
| **Stage**            |                 |                   | 0.594   |
| I                    | 29831 (70.46)   | 14935 (70.55)     |         |
| II                   | 3458 (8.17)     | 1677 (7.92)       |         |
| III                  | 6623 (15.64)    | 3336 (15.76)      |         |
| IV                   | 2428 (5.73)     | 1222 (5.77)       |         |
| **Chemotherapy**     |                 |                   | 0.082   |
| No                   | 34276 (80.95)   | 17026 (80.43)     |         |
| Yes                  | 8064 (19.05)    | 4144 (19.57)      |         |
| **Radiation**        |                 |                   | 0.052   |

EEA, endometrial endometrioid adenocarcinoma; SEA, serous endometrioid adenocarcinoma; LNM, lymph node metastasis
|                         | Training cohort | Validation cohort | P    |
|-------------------------|-----------------|-------------------|------|
| No                      | 30202 (71.33)   | 15044 (71.06)     |      |
| Yes                     | 12138 (28.67)   | 6126 (28.94)      |      |
| Overall survival        |                 |                   | 0.778|
| Alive                   | 32905 (77.72)   | 16435 (77.63)     |      |
| Death                   | 9435 (22.28)    | 4735 (22.37)      |      |
| Cancer-specific survival|                 |                   | 0.972|
| Alive                   | 35695 (84.31)   | 17791 (84.04)     |      |
| Death                   | 6645 (15.69)    | 3379 (15.96)      |      |

EEA, endometrial endometrioid adenocarcinoma; SEA, serous endometrioid adenocarcinoma; LNM, lymph node metastasis

**Independent prognostic factors for OS and CSS**

The univariate and multivariate analyses of potential predictors for the OS in the training group and the validation group are shown in Table 2. Age at diagnosis, marital status, tumor size, histological type, myometrial invasion, cervical stromal invasion, lymph node metastasis, tumor grade, clinical stage, chemotherapy, radiotherapy were significantly associated as risk factors for the OS according to univariate analysis for both the groups. For this reason, these risk factors were included in the multivariate analysis. Multivariate analysis identified that age at diagnosis (51–60, OR = 1.37, 95%CI: 1.15–1.63, p = 0.004; 61–70, OR = 2.17, 95%CI: 1.82–2.58, p < 0.001; >70, OR = 4.01, 95%CI: 3.37–4.77, p < 0.001), marital status (single, OR = 1.39, 95%CI: 1.31–1.47, p < 0.001; others, OR = 1.46, 95%CI: 1.39–1.52, p < 0.001), tumor size (2.1-5cm, OR = 1.13, 95%CI: 1.06–1.20, p < 0.001; 5.1-10cm, OR = 1.39, 95%CI: 1.30–1.49, p < 0.001; >10 cm, OR = 1.75, 95%CI: 1.60–1.92 p < 0.001), histological type (SEA, OR = 1.13, 95%CI: 1.06–1.21, p < 0.001; other types, OR = 1.53, 95%CI: 1.43–1.64, p < 0.001), lymph node metastasis (OR = 1.36, 95%CI: 1.28–1.44, p < 0.001), tumor grade (G2, OR = 1.45, 95%CI: 1.36–1.54, p < 0.001; G3, OR = 2.62, 95%CI: 2.46–2.79, p < 0.001), clinical stage (stage II, OR = 1.24, 95%CI: 1.15–1.35, p < 0.001; stage III, OR = 1.73, 95%CI: 1.61–1.86, p < 0.001; stage IV, OR = 4.92, 95%CI: 4.54–5.34, p < 0.001) were independent risk factors to predict OS in the training group. The analysis of the validation group showed similar results (Table 2). These variables remained statistically significant (p < 0.01) according to the multivariate analysis for CSS (Table 3). For this reason, age at diagnosis, marital status, tumor size, histological type, lymph node metastasis, tumor grade, and clinical stage were identified as independent prognostic factors for both OS and CSS for the EC patients. Independent prognostic factors were used to develop the nomograms for 3-year and 5-year OS and CSS (Fig. 2A and Fig. 2B). Detailed points of each
predictor in the nomograms were listed in Table 4. By including these scores to the total on the bottom scale, the 3- and 5-year OS and CSS can be predicted.
Table 2  
Univariate and multivariate analysis of overall survival in training and validation cohorts

|                              | Training cohort | Validation cohort |
|------------------------------|-----------------|-------------------|
|                              | Univariate      | Multivariate      | Univariate      | Multivariate      |
| Age at diagnosis             |                 |                   |                 |                   |
| ≤ 40                         | 1.0             | 1.0               | 1.0             | 1.0               |
| 41–50                        | 1.13 (0.93, 1.37)| 1.08 (0.89, 1.31) | 1.00 (0.77, 1.29)| 1.04 (0.80, 1.36) |
|                              | 0.2093          | 0.4095            | 0.9711          | 0.7544            |
| 51–60                        | 1.47 (1.23, 1.74)| 1.37 (1.15, 1.63) | 1.35 (1.06, 1.71)| 1.36 (1.07, 1.73) |
|                              | < 0.001         | 0.004             | 0.0140          | 0.0115            |
| 61–70                        | 2.56 (2.16, 3.04)| 2.17 (1.82, 2.58) | 2.22 (1.76, 2.81)| 2.01 (1.58, 2.54) |
|                              | < 0.001         | < 0.001           | < 0.001         | < 0.001           |
| > 70                         | 5.83 (4.92, 6.92)| 4.01 (3.37, 4.77) | 4.95 (3.92, 6.24)| 3.78 (2.98, 4.79) |
|                              | < 0.001         | < 0.001           | < 0.001         | < 0.001           |
| Marital status               |                 |                   |                 |                   |
| Married                      | 1.0             | 1.0               | 1.0             | 1.0               |
| Single                       | 1.28 (1.21, 1.36)| 1.39 (1.31, 1.47) | 1.23 (1.14, 1.34)| 1.27 (1.17, 1.37) |
|                              | < 0.001         | < 0.001           | < 0.001         | < 0.001           |
| Others                       | 2.07 (1.98, 2.17)| 1.46 (1.39, 1.52) | 2.06 (1.94, 2.20)| 1.39 (1.30, 1.48) |
|                              | < 0.001         | < 0.001           | < 0.001         | < 0.001           |
| Tumor size (cm)              |                 |                   |                 |                   |
| ≤ 2                          | 1.0             | 1.0               | 1.0             | 1.0               |
| 2.1–5                        | 1.66 (1.56, 1.76)| 1.13 (1.06, 1.20) | 1.67 (1.53, 1.82)| 1.14 (1.05, 1.25) |
|                              | < 0.001         | 0.001             | < 0.001         | 0.0026            |
| 5.1–10                       | 3.10 (2.91, 3.31)| 1.39 (1.30, 1.49) | 3.23 (2.95, 3.54)| 1.54 (1.40, 1.70) |
|                              | < 0.001         | < 0.001           | < 0.001         | < 0.001           |
| > 10                         | 3.24 (2.98, 3.53)| 1.75 (1.60, 1.92) | 3.28 (2.91, 3.71)| 1.90 (1.67, 2.16) |
|                              | < 0.001         | < 0.001           | < 0.001         | < 0.001           |
| Histological type            |                 |                   |                 |                   |
| EEA                          | 1.0             | 1.0               | 1.0             | 1.0               |
| SEA                          | 3.22 (3.04, 3.41)| 1.13 (1.06, 1.21) | 3.20 (2.95, 3.47)| 1.12 (1.03, 1.22) |
|                              | < 0.001         | 0.001             | < 0.001         | 0.0101            |

EEA, endometrial endometrioid adenocarcinoma; SEA, serous endometrioid adenocarcinoma; LNM, lymph node metastasis
|                     | Training cohort          | Validation cohort          |
|---------------------|--------------------------|----------------------------|
| Other types         | 3.14 (2.94, 3.35) < 0.001| 1.53 (1.43, 1.64) < 0.001  |
|                     | 2.98 (2.71, 3.27) < 0.001| 1.43 (1.29, 1.57) < 0.001  |
| Myometrial invasion |                          |                            |
| < 50                | 1.0                      | 1.0                        |
| >= 50               | 3.18 (2.96, 3.43) < 0.001| 2.83 (2.56, 3.12) < 0.001  |
| Cervical invasion   |                          |                            |
| Negative            | 1.0                      | 1.0                        |
| Positive            | 3.74 (3.58, 3.91) < 0.001| 3.76 (3.53, 4.00) < 0.001  |
| LNM                 |                          |                            |
| Negative            | 1.0                      | 1.0                        |
| Positive            | 4.08 (3.90, 4.27) < 0.001| 4.12 (3.86, 4.39) < 0.001  |
| Tumor grade         |                          |                            |
| 1                   | 1.0                      | 1.0                        |
| 2                   | 1.98 (1.86, 2.10) < 0.001| 1.85 (1.69, 2.01) < 0.001  |
| 3                   | 5.88 (5.57, 6.20) < 0.001| 5.85 (5.42, 6.31) < 0.001  |
| Stage               |                          |                            |
| I                   | 1.0                      | 1.0                        |
| II                  | 2.11 (1.97, 2.27) < 0.001| 2.10 (1.90, 2.34) < 0.001  |
| III                 | 3.67 (3.49, 3.86) < 0.001| 3.88 (3.62, 4.15) < 0.001  |
| IV                  | 13.17 (12.45, 13.93) < 0.001| 14.07 (13.00, 15.23) < 0.001| 5.04 (4.52, 5.61) < 0.001 |
| Chemotherapy        |                          |                            |
| 0                   | 1.0                      | 1.0                        |

EEA, endometrial endometrioid adenocarcinoma; SEA, serous endometrioid adenocarcinoma; LNM, lymph node metastasis
|                | Training cohort | Validation cohort |
|----------------|-----------------|-------------------|
|                |                 | 2.82 (2.70, 2.94) | 2.71 (2.55, 2.88) |
|                |                 | < 0.001           | < 0.001           |
| Radiation      | 0               | 1.0               | 1.0               |
|                | 1               | 1.34 (1.28, 1.39) | 1.32 (1.24, 1.40) |
|                |                 | < 0.001           | < 0.001           |

EEA, endometrial endometrioid adenocarcinoma; SEA, serous endometrioid adenocarcinoma; LNM, lymph node metastasis
Table 3
Univariate and multivariate analysis of cancer-specific survival in training and validation cohorts

|                      | Training cohort | Validation cohort |
|----------------------|-----------------|-------------------|
|                      | Univariate      | Multivariate      | Univariate      | Multivariate      |
| **Age (year)**       |                 |                   |                 |                   |
| ≤ 40                 | 1.0             | 1.0               | 1.0             | 1.0               |
| 41–50                | 1.12 (0.91, 1.39) | 0.2910           | 1.09 (0.90, 1.32) | 0.3924           | 1.03 (0.76, 1.38) | 0.8671           | 1.04 (0.77, 1.40) | 0.7927           |
| 51–60                | 1.43 (1.17, 1.74) | 0.004             | 1.36 (1.14, 1.62) | 0.006             | 1.33 (1.01, 1.74) | 0.0407             | 1.26 (0.96, 1.66) | 0.0964           |
| 61–70                | 2.31 (1.90, 2.80) | < 0.001           | 2.17 (1.82, 2.57) | < 0.001           | 2.12 (1.62, 2.76) | < 0.001           | 1.71 (1.30, 2.24) | < 0.001           |
| > 70                 | 4.57 (3.77, 5.54) | < 0.001           | 4.15 (3.49, 4.93) | < 0.001           | 4.05 (3.11, 5.28) | < 0.001           | 2.68 (2.04, 3.52) | < 0.001           |
| **Marital status**   |                 |                   |                 |                   |
| Married              | 1.0             | 1.0               | 1.0             | 1.0               |
| Single               | 1.27 (1.19, 1.36) | < 0.001           | 1.41 (1.33, 1.49) | < 0.001           | 1.16 (1.05, 1.28) | 0.0023             | 1.12 (1.02, 1.24) | 0.0206           |
| Others               | 1.86 (1.77, 1.97) | < 0.001           | 1.48 (1.41, 1.54) | < 0.001           | 1.91 (1.77, 2.05) | < 0.001           | 1.30 (1.21, 1.41) | < 0.001           |
| **Tumor size (cm)**  |                 |                   |                 |                   |
| ≤ 2                  | 1.0             | 1.0               | 1.0             | 1.0               |
| 2.1–5                | 1.82 (1.69, 1.97) | < 0.001           | 1.11 (1.04, 1.18) | 0.0010             | 1.75 (1.57, 1.95) | < 0.001           | 1.10 (0.98, 1.22) | 0.1043           |
| 5.1–10               | 3.99 (3.68, 4.32) | < 0.001           | 1.34 (1.26, 1.44) | < 0.001           | 3.98 (3.57, 4.45) | < 0.001           | 1.51 (1.35, 1.70) | < 0.001           |
| >10                  | 4.52 (4.09, 5.00) | < 0.001           | 1.75 (1.60, 1.91) | < 0.001           | 4.41 (3.83, 5.08) | < 0.001           | 1.92 (1.65, 2.22) | < 0.001           |
| **Histological type**|                 |                   |                 |                   |
| EEA                  | 1.0             | 1.0               | 1.0             | 1.0               |
| SEA                  | 4.05 (3.80, 4.31) | < 0.001           | 1.10 (1.04, 1.17) | 0.0021             | 4.01 (3.67, 4.38) | < 0.001           | 1.17 (1.06, 1.29) | 0.0014           |

EEA, endometrial endometrioid adenocarcinoma; SEA, serous endometrioid adenocarcinoma; LNM, lymph node metastasis
|                        | Training cohort | Validation cohort |
|------------------------|-----------------|-------------------|
| **Histological type**  |                 |                   |
|                        | 4.05 (3.76, 4.36) < 0.001 | 1.52 (1.42, 1.63) < 0.001 |
|                        |                 | 3.73 (3.36, 4.15) < 0.001 |
|                        |                 | 1.50 (1.35, 1.67) < 0.001 |
| **Myometrial invasion**|                 |                   |
| < 50                   | 1.0             | 1.0               |
| ≥ 50                   | 4.11 (3.72, 4.54) < 0.001 | 4.03 (3.51, 4.63) < 0.001 |
| **Cervical invasion**  |                 |                   |
| Negative               | 1.0             | 1.0               |
| Positive               | 5.26 (4.97, 5.57) < 0.001 | 5.35 (4.93, 5.80) < 0.001 |
| **LNM**                |                 |                   |
| Negative               | 1.0             | 1.0               |
| Positive               | 5.42 (5.15, 5.71) < 0.001 | 5.42 (5.04, 5.82) < 0.001 |
| **Grade**              |                 |                   |
| 1                      | 1.0             | 1.0               |
| 2                      | 2.65 (2.43, 2.88) < 0.001 | 2.34 (2.08, 2.63) < 0.001 |
| 3                      | 2.39 (2.25, 2.55) < 0.001 | 2.39 (2.25, 2.55) < 0.001 |
| **Stage**              |                 |                   |
| I                      | 1.0             | 1.0               |
| II                     | 2.60 (2.38, 2.85) < 0.001 | 2.34 (2.08, 2.63) < 0.001 |
| III                    | 5.57 (5.24, 5.91) < 0.001 | 5.88 (5.41, 6.39) < 0.001 |
| IV                     | 21.67 (20.33, 23.11) < 0.001 | 22.45 (20.50, 24.58) < 0.001 |
| **Chemotherapy**       |                 |                   |
| 0                      | 1.0             | 1.0               |

EEA, endometrial endometrioid adenocarcinoma; SEA, serous endometrioid adenocarcinoma; LNM, lymph node metastasis
|               | Training cohort                  | Validation cohort                  |
|---------------|----------------------------------|-----------------------------------|
| **1**         | 3.94 (3.76, 4.14) < 0.001        | 3.75 (3.50, 4.01) < 0.001         |
| **Radiation** |                                  |                                   |
| **0**         | 1.0                              | 1.0                               |
| **1**         | 1.47 (1.39, 1.54) < 0.001        | 1.46 (1.36, 1.57) < 0.001         |

EEA, endometrial endometrioid adenocarcinoma; SEA, serous endometrioid adenocarcinoma; LNM, lymph node metastasis
Table 4
Detailed score of each prognostic factor in overall and cancer-specific survival nomograms

| Characteristics    | OS nomogram | CSS nomogram |
|--------------------|-------------|--------------|
| **Age at diagnosis** |             |              |
| ≤ 40               | 0           | 0            |
| 41–50              | 5           | 2.5          |
| 51–60              | 18          | 12           |
| 61–70              | 45          | 28           |
| > 70               | 82          | 52.5         |
| **Marital status** |             |              |
| Married            | 0           | 0            |
| Single             | 18          | 13           |
| Others             | 21          | 15           |
| **Tumor size (cm)**|             |              |
| ≤ 2                | 0           | 0            |
| 2.1–5              | 10          | 8            |
| 5.1–10             | 20          | 20           |
| > 10               | 33          | 30           |
| **Histological type** |         |              |
| EEA                | 0           | 0            |
| SEA                | 5           | 7.5          |
| Other types        | 23          | 23           |
| **LNM**            |             |              |
| Negative           | 0           | 0            |
| Positive           | 15          | 12.5         |
| **Tumor grade**    |             |              |
| 1                  | 0           | 0            |
| 2                  | 20          | 28           |

EEA, endometrial endometrioid adenocarcinoma; SEA, serous endometrioid adenocarcinoma; LNM, lymph node metastasis
Calibration and discrimination of the nomograms

Internal and external validations of the prognostic nomograms were performed. Internal validation in the training cohort showed that the C-index values for nomogram predictions of OS and CSS were 0.816 (95%CI: 0.811–0.820) and 0.850 (95%CI: 0.846–0.855), respectively. Similarly, the corresponding C-index values in the external validation cohort were 0.812 (95%CI: 0.806–0.819) and 0.847 (95%CI: 0.841–0.854). These results confirmed that our prognostic nomograms were reasonably accurate. The calibration curves estimating the 3- and the 5-year OS and CSS rates showed accordance between the nomogram-predicted and observed values in both the training and the validation groups (Fig. 3).

Furthermore, predictive accuracy and differentiation of patients were compared between the nomogram and the clinical stage system. In the training group, the AUC of the established nomogram (AUC = 0.83, 95%CI: 0.71–0.87) to predict OS was significantly higher than that of the clinical stage (AUC = 0.73, 95%CI: 0.67–0.80, p < 0.01; Fig. 4A). While for the CSS, the AUC of the nomogram (AUC = 0.87, 95%CI: 0.85–0.90) was also greater than that of the clinical stage (AUC = 0.79, 95%CI: 0.71–0.84, p < 0.01; Fig. 4B). The analysis of the validation group showed similar results (Fig. 4C and Fig. 4D). The nomograms for OS and CSS showed superior discrimination as compared to the clinical stage both in the training and the validation cohorts.

Performance of the nomogram in stratifying the risk for EC patients

We determined the cutoff values by dividing the patients in the training cohort evenly into 5 subgroups after sorting by the total OS score (score: 0–45, 46–73, 74–103, 104–143, 144–342) and the total CSS score (score: 0-35.5, 36-60.5, 61-88.5, 89-132.5, 133–293), and each group represented a distinct prognosis (Fig. 5). As shown in Fig. 5A, the mortality of patients in the low-score group was 3.98%, and

| Characteristics | OS nomogram | CSS nomogram |
|-----------------|-------------|--------------|
| Stage           |             |              |
| I               | 0           | 0            |
| II              | 25          | 28           |
| III             | 40          | 47           |
| IV              | 100         | 100          |

EEA, endometrial endometrioid adenocarcinoma; SEA, serous endometrioid adenocarcinoma; LNM, lymph node metastasis
reached the 59.19% value in the high-score group. After applying the cutoff values to the groups of patients in the different clinical staging cohorts, stratification into different risk subgroups in both the training and validation groups ensured a significant distinction between Kaplan-Meier curves for OS and the CSS outcomes within each clinical stage category (Fig. 6 and supplementary Fig. 1). For patients in stage IA, the overall survival was very different in the different subgroups. As an example, in patients in stage IA whose OS score was greater than 144, the mortality was as high as 44.44% (Fig. 6A), and patients in stage III-IV whose OS score was less than 73, the mortality was lower than 7.83% (Fig. 6D). Using this methodology, we could not only select high-risk patients at low stages, but also distinguish low-risk patients at high stages.

**Discussion**

The clinical staging system is the most common method to predict the prognosis in endometrial cancer. The 2009 FIGO staging system included many of the known risk factors for OS and CSS, such as myometrial invasion, cervical stromal invasion, and lymph node metastasis. However, other important risk factors including age at diagnosis, tumor grade, and histologic type that may affect the survival, are not currently included in the FIGO system. Furthermore, in order to predict the individual survival probability, a single prognostic index may impose limitations on the individual prognosis. Accurate individual prognosis helps to avoid oncological under-treatment or over-treatment in EC patients.

Nomogram is a common graphic prediction tool that can provide a more precise and acceptable accuracy and robustness to predict an individual patient’s survival probability.

In this study, we developed prognostic nomograms to predict the overall survival and cancer-specific survival using univariate log-rank and multivariate Cox analyses using a large population-based database. Several clinicopathological characteristics have proven to be independent from other risk factors such as age at diagnosis, marital status, tumor size, histological type, lymph node metastasis, tumor grade, and clinical stage. Our nomograms identified these seven independent risk factors to determine the survival of EC patients and provided with an internal validation for the nomograms predicting the 3- and the 5-year OS and CSS in EC patients. Abu-Rustum constructed the first nomogram based on 5 variables to predict the OS and the study was based on 1,735 patients who received the treatment at the MSKCC in New York City [12]. The internal validation showed a C-index of 0.75, which represents an acceptable value for the patient differentiation between the subjects who died as compared to those who survived. However, the authors did not included the marital status and the tumor size as additional risk factors. A previous study demonstrated that married women affected by EC showed a favorable diagnosis and prognosis [16]. We observed a similar trend also in our study where single women (including widows or divorced women) had a higher risk of mortality as compared to married women.

A previous study demonstrated that large tumor size is an important risk factor for a multitude of tumors including bladder [17], lung [18], and prostate cancers [19]. Our study suggested that patients with large tumors had a diminished survival as compared to those with smaller size tumors. Koskas and colleagues
and Polterauer et al. validated the Abu-Rustum's nomogram using an external cohorts, and proved that the nomogram could accurately predict the 3-year overall survival \cite{20,21}. They also found that the nomogram is sufficient even for EC patients receiving adjuvant radiotherapy or not. Radiotherapy was found to be an independent risk factor for breast cancer and prostate cancer \cite{22,23}. The reason why EC nomogram was not included in Abu-Rustum's and our nomogram might be that the patients who underwent adjuvant radiotherapy and adjuvant chemotherapy were older and had an higher grade histology. Additionally, adjuvant therapy was only recommended for a subset of patients who had potentially an high risk of disease recurrence. The adjuvant therapies, when included into the nomogram, have a contradictory impact on the treated and untreated populations, determining the assignment of a wrong score to the untreated patients. Compared with the MSKCC nomogram, our nomogram has been developed from a relatively larger cohort and predicted not only the overall survival but also the cancer-specific survival. The determined C-index for our OS nomogram was 0.816, which is greater than any of the MSKCC internal validation or external groups.

The validation of the nomogram is essential to avoid overfitting of the model and determine the scope of its application. In this study, calibration plots revealed an ideal accordance between the prediction and the actual observation in both the training and the validation groups, which illustrated the repeatability and reliability of the OS and the CSS nomograms. Patient differentiation was determined through a significantly higher AUC of the nomogram as compared to the FIGO staging system in both the cohorts. Historically, the FIGO staging system helped to standardize the therapeutic management and predict the OS. Our prognostic nomograms attempted to combine the FIGO staging system with other determinant clinical factors in order to predict the individual's survival outcome in all EC stages. Therefore, our nomogram represents a more accurate individual performance predicting prognosis as compared to the 2009 FIGO staging systems for EC. Our study revealed that the AUCs of the nomograms for OS and CSS were both greater than the AUCs as determined by the FIGO staging system, suggesting that the nomograms are more accurate in predicting the OS and CSS in EC patients. We also found that the MSKCC nomogram was more accurate than the 2009 FIGO staging system in predicting the OS \cite{24}.

For a more detailed validation of the nomograms, we calculated the total scores for each patient and divided the patients into 5 subgroups (OS score: 0–45, 46–73, 74–103, 104–143, 144–342; CSS score: 0–35.5, 36–60.5, 61–88.5, 89–132.5, 133–293) according to the total scores. According to our data, the survival rate of patients in the low score subgroup was always higher than patients belonging to the high score group, either for the OS and the CSS. The scoring system can also precisely differentiate patients in the same clinical stage but with a worse prognosis, which can be determinant in the context of an individualized treatment and of the precise therapy.

To the best of our knowledge, this was the first study predicting both OS and CSS based on a large population with a long term follow-up. However, some limitations can affect our study. First, we developed and validated the nomograms using retrospective data. Although we collected the largest cohort using the SEER database which represents ~30% of the US population, the nomograms need to be validated in a randomized controlled trial for a better reliability. The second limitation was that several
recognized prognostic parameters, such as lymph-vascular space invasion (LVSI), serum CA-125 level, and chronic disease history, were unavailable in the SEER database. Third, the external validation of the nomogram in this study needs to be explored using prospective datasets.

Conclusion

After all, we developed and validated nomograms which predicted the 3- and the 5-year OS and CSS in EC patients based on a large, population-based cohort. The nomogram demonstrated an higher predictive accuracy than the FIGO staging system. Through this model, gynecologic oncologists could estimate the survival of individual patients more precisely and identify subgroups of patients needing a specific treatment strategy.

Abbreviation

OS, overall survival; CSS, cancer-specific survival; EC, endometrial cancer; SEER, Surveillance, Epidemiology, and End Results database; C-index, concordance index; ROC, receiver operating characteristics, FIGO, International Federation of Gynecology and Obstetrics; MSKCC, Memorial Sloan Kettering Cancer Center; EEA, endometrial endometrioid adenocarcinoma; SEA, serous endometrioid adenocarcinoma; AUC, area under the ROC curve; HR, hazard ratios, CI, confidence interval;

Declarations

Ethics approval and consent to participate

The research was approved by the Institute Research Medical Ethics Committee of Peking University People's Hospital.

Consent for publication

All authors read and approved the final manuscript.

Availability of data and materials

Not applicable.

Competing interests

We declare that we have no conflict of interest.

Funding

This study was funded by the grants from the National Natural Science Foundation of China (Grant No 81874108, 81672571 and 81802607), Beijing Municipal Natural Science Foundation (Grant No 7202213), and National Key Technology R&D Program of China (nos. 2019YFC1005200 and 2019YFC1005201)
Authors' contributions

Conceptualization: J.L.W. and X.C.L.; Methodology: Y.Y.D. and Y.C. Software: X.Y.; Formal Analysis: J.Q.W. and B.Q.S.; Investigation: J.L.W. and Y.Y.D. Resources: L.J.Z. and X.P.L. Data Curation: Z.Q.W. Writing – Original Draft Preparation: X.C.L. Writing – Review & Editing: Y.Y.D. and J.L.W. Funding Acquisition: J.L.W. and Y.C. All authors read and approved the manuscript.

Acknowledgements

We especially appreciate Jiayang Jin, PhD of Peking University People’s Hospital Rheumatology department for study design consultations and editing the manuscript.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018, 68(1):7-30
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016, 66(2):115-132
3. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet 2016, 387(10023):1094-1108
4. Erkilinc S, Taylan E, Gulseren V, Erkilinc G, Karadeniz T, Bagci M, et al. The Effect of Adenomyosis in Myometrial Invasion and Overall Survival in Endometrial Cancer. Int J Gynecol Cancer 2018, 28(1):145-151
5. Tanaka K, Kobayashi Y, Sugiyama J, Yamazaki T, Dozono K, Watanabe M, et al. Histologic grade and peritoneal cytology as prognostic factors in type 1 endometrial cancer. Int J Clin Oncol 2017, 22(3):533-540
6. Chen S, Liu Y, Yang J, Liu Q, You H, Dong Y, et al. Development and Validation of a Nomogram for Predicting Survival in Male Patients With Breast Cancer. Front Oncol 2019, 9(361)
7. Yu CZ, Zhang Y. Development and validation of prognostic nomogram for young patients with gastric cancer. Ann Transl Med 2019, 7(22):641
8. Bogani G, Tagliabue E, Signorelli M, Ditto A, Martinelli F, Chiappa V, et al. A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses. J Gynecol Oncol 2018, 29(3):e40
9. Dong Y, Cheng Y, Tian W, Zhang H, Wang Z, Li X, et al. An Externally Validated Nomogram for Predicting Lymph Node Metastasis of Presumed Stage I and II Endometrial Cancer. Front Oncol 2019, 9(1218)
10. Ouldamer L, Bendifallah S, Body G, Touboul C, Graesslin O, Raimond E, et al. Predicting poor prognosis recurrence in women with endometrial cancer: a nomogram developed by the FRANCOGYN study group. Br J Cancer 2016, 115(11):1296-1303
11. AlHilli MM, Podratz KC, Dowdy SC, Bakkum-Gamez JN, Weaver AL, McGree ME, et al. Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer. Gynecol Oncol 2013, 131(1):103-108

12. Abu-Rustum NR, Zhou Q, Gomez JD, Alektiar KM, Hensley ML, Soslow RA, et al. A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. Gynecol Oncol 2010, 116(3):399-403

13. Doll KM, Rademaker AS, Sosa JA. Practical Guide to Surgical Data Sets: Surveillance, Epidemiology, and End Results (SEER) Database. JAMA Surg 2018, 153(6):588-589

14. Steyerberg EW, Eijkemans MJ, Harrell FE, Jr., Habbema JD. Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med 2000, 19(8):1059-1079

15. Royston PA, Altman DG. External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol 2013, 13(3)

16. Dong J, Dai Q, Zhang F. The effect of marital status on endometrial cancer-related diagnosis and prognosis: a Surveillance Epidemiology and End Results database analysis. Future Oncol 2019, 15(34):3963-3976

17. Wakai K, Utsumi T, Yoneda K, Oka R, Endo T, Yano M, et al. Development and external validation of a nomogram to predict high-grade papillary bladder cancer before first-time transurethral resection of the bladder tumor. Int J Clin Oncol 2018, 23(5):957-964

18. Du Q, Yan C, Wu SG, Zhang W, Huang C, Yao Y, et al. Development and validation of a novel diagnostic nomogram model based on tumor markers for assessing cancer risk of pulmonary lesions: A multicenter study in Chinese population. Cancer Lett 2018, 420(236-241

19. Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013, 31(14):1748-1757

20. Koskas M, Bendifallah S, Luton D, Darai ER, Rouzier R. Independent external validation of radiotherapy and its impact on the accuracy of a nomogram for predicting survival of women with endometrial cancer. Gynecol Oncol 2011, 123(2):214-220

21. Polterauer S, Zhou Q, Grimm C, Seebacher V, Reinthaller A, Hofstetter G, et al. External validation of a nomogram predicting overall survival of patients diagnosed with endometrial cancer. Gynecol Oncol 2012, 125(3):526-530

22. Li S, Zhao J, Zhu L, Su F, Chen K. Development and validation of a nomogram predicting the overall survival of stage IV breast cancer patients. Cancer Med 2017, 6(11):2586-2594

23. Hwang WL, Tendulkar RD, Niemierko A, Agrawal S, Stephens KL, Spratt DE, et al. Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. JAMA Oncol 2018, 4(5):e175230

24. Huss A, Ihorst G, Timme-Bronsert S, Hasenburg A, Oehler MK, Klar M. The Memorial Sloan Kettering Cancer Center Nomogram is More Accurate than the 2009 FIGO Staging System in the Prediction of
Overall Survival in a German Endometrial Cancer Patient Cohort. Ann Surg Oncol 2018, 25(13):3966-3973

Figures

Figure 1

Patients diagnosed as EC between 2004 and 2015 (N=145445)

Exclude patients with a history of previous malignancy (N=7928)

Exclude patients whose age ≤ 18 years old (N=22)

Patients with unknown information
Marital status (N=8335)
Tumor size (N=12182)
Histology (N=6838)
Myometrial invasion (N=7940)
Cervical incasion (N=8956)
Lymph node metastasis (N=9817)
Tumor grade (N=9485)
Clinical stage (N=6284)
Chemotherapy (N=1983)
Radiotherapy (N=2165)

Eligible EC patients (N=63510)

Training cohort (N=42340)

Training cohort (N=21170)
Flow diagram of inclusion criteria and exclusion criteria. According to the criteria, 145440 patients were collected from the SEER database and randomly assigned into the training cohort (N=42340) and validation cohort (N=21170).

Figure 2

A

| Points | 0 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90 | 100 |
|--------|---|----|----|----|----|----|----|----|----|----|-----|
| Age    |   |    |    |    |    |    |    |    |    |    | 40-49 |
|        | <40| 50-59|    |    |    |    |    |    |    |    | >=70 |
| Marital| 1 | 2   | 3  | 4  |    |    |    |    |    |    |     |
| Size   | 1 | 2   | 3  | 4  |    |    |    |    |    |    |     |
| Histology | 2 | 3  |    |    |    |    |    |    |    |    |     |
| LNM    | 1 | 2   |    |    |    |    |    |    |    |    |     |
| Grade  | 1 | 2   |    |    |    |    |    |    |    |    |     |
| Stage  | 1 | 2   |    |    |    |    |    |    |    |    | 4    |

Total Points

3-Year Survival

0.9 | 0.8 | 0.7 | 0.6 | 0.5 | 0.4 | 0.3 | 0.2 | 0.1

5-Year survival

0.9 | 0.8 | 0.7 | 0.6 | 0.5 | 0.4 | 0.3 | 0.2 | 0.1

B

| Points | 0 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90 | 100 |
|--------|---|----|----|----|----|----|----|----|----|----|-----|
| Age    |   |    |    |    |    |    |    |    |    |    | 40-49 |
|        | <40| 50-59|    |    |    |    |    |    |    |    | >=70 |
| Marital| 1 | 2   | 3  | 4  |    |    |    |    |    |    |     |
| Size   | 1 | 2   | 3  | 4  |    |    |    |    |    |    |     |
| Histology | 2 | 3  |    |    |    |    |    |    |    |    |     |
| LNM    | 1 | 2   |    |    |    |    |    |    |    |    |     |
| Grade  | 1 | 2   |    |    |    |    |    |    |    |    |     |
| Stage  | 1 | 2   |    |    |    |    |    |    |    |    | 4    |

Total Points

3-Year Survival

0.9 | 0.8 | 0.7 | 0.6 | 0.5 | 0.4 | 0.3 | 0.2 | 0.1

5-Year survival

0.9 | 0.8 | 0.7 | 0.6 | 0.5 | 0.4 | 0.3 | 0.2 | 0.1

Figure 2

Nomogram to predict 3- and 5-year (A) overall survival and (B) cancer-specific survival for endometrial cancer patients. EEA, endometrial endometrioid adenocarcinoma; SEA, serous endometrioid
adenocarcinoma; LNM, lymph node metastasis.

Figure 3

Internal calibration plots of (A) 3- and 5-year overall survival in training group, (B) 3- and 5-year cancer-specific survival in training group, (C) 3- and 5-year overall survival in validation group, (D) 3- and 5-year cancer-specific survival in validation group. The dashed line represents an excellent match between nomogram predicted survival (X-axis) and actual survival outcome (Y-axis). A plot along the dashed line indicates a perfect calibration model.
Figure 4

Area under the receiver operating characteristic curves (AUCs) of nomograms and FIGO staging system for the prediction of overall survival (OS) and cancer-specific survival (CSS) in EC in training and validation cohorts. AUCs comparison in (A) OS in training cohort, (B) CSS in training cohort, (C) OS in validation cohort, (D) CSS in validation cohort. Model 1: nomogram; Model 2: FIGO staging system.
Figure 5

Overall and cancer specific survival in different risk stratifications. Patients were divided into 5 groups according to their total OS or CSS score. (A) OS in training cohort, (B) CSS in training cohort, (C) OS in validation cohort, (D) CSS in validation.
Figure 6

Risk group stratification within each FIGO staging system in the training group. (A) OS in stage IA, (B) OS in stage IB, (C) OS in stage II, (D) OS in stage III-IV, (E) CSS in stage IA, (F) CSS in stage IB, (G) CSS in stage II, (H) CSS in stage III-IV

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

- suppFigure1OS.tif